{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:27Z","timestamp":1790805867044,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Paroxysmal nocturnal hemoglobinuria is a clonal hematopoietic stem cell disorder resulting in complement-mediated hemolysis. Eculizumab, a monoclonal antibody against complement protein C5, has been shown to reduce both intravascular hemolysis and risk for thrombosis, and thereby improve the quality of life in these patients. While the infection risk from <jats:italic toggle=\"yes\">Neisseria meningitidis<\/jats:italic> due to terminal complement blockade can be mitigated with appropriate immunizations and prophylactic antibiotics, these patients remain vulnerable to infections from <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>. Physicians and families should be aware of disseminated and severe gonococcal infections in patients receiving complement blockade, especially in this era of emerging cephalosporin and azithromycin resistance.<\/jats:p>","DOI":"10.1097\/mph.0000000000002075","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T23:56:04Z","timestamp":1613951764000},"page":"e493-e495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade"],"prefix":"10.1097","volume":"44","author":[{"given":"Sara H.","family":"Graciaa","sequence":"first","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Graciaa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inci","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and Global Health, Department of Pediatrics, Yale University School of Medicine"},{"name":"Institute for Global Health, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheesh","family":"Chonat","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta"},{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"R1-20250805","first-page":"1","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nature"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jinf.2018.10.015","article-title":"Unusual Neisseria species as a cause of infection in patients taking eculizumab","volume":"78","author":"Crew","year":"2019","journal-title":"J Infect"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00005792-198311000-00005","article-title":"Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms","volume":"62","author":"O\u2019Brien","year":"1983","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving Eculizumab: a case series","volume":"69","author":"Crew","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6507a1","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility surveillance - the gonococcal isolate surveillance project, 27 Sites, United States, 2014","volume":"65","author":"Kirkcaldy","year":"2016","journal-title":"MMWR Surveill Summ"},{"issue":"RR-03","key":"R11-20250805","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/vaccines7010005","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3389\/fimmu.2019.02417","article-title":"Progress toward a gonococcal vaccine: the way forward","volume":"10","author":"Russell","year":"2019","journal-title":"Front Immunol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:00:11Z","timestamp":1754355611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002075","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"2020-11-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}